首页 > 最新文献

Metabolism open最新文献

英文 中文
Clinical diagnosis, treatment, and genetic analysis of adolescent onset holocarboxylase synthetase deficiency and cobalamin C deficiency: A case report and literature review 青少年发作的全新羧化酶合成酶缺乏症和钴胺素C缺乏症的临床诊断、治疗和遗传分析:1例报告并文献复习
Pub Date : 2025-06-01 Epub Date: 2025-03-22 DOI: 10.1016/j.metop.2025.100361
Ye Ren , Hongxing Dang , Yueqiang Fu , Chengjun Liu , Jing Li , Jinhua Cai

Background

Holocarboxylase Synthetase Deficiency (HCSD) is an uncommon autosomal recessive genetic disorder that manifests with symptoms such as metabolic acidosis, lethargy, hypotonia, seizures, and persistent rashes, typically emerging during infancy. The HLCS gene has been identified as the source of pathogenic mutations associated with this condition. Cobalamin C (cblC) deficiency is another rare autosomal recessive disorder resulting from defects in cobalamin metabolism, attributable to mutations in the MMACHC gene. This disorder often leads to methylmalonic aciduria and homocystinuria and is classified into early-onset and late-onset types. The late-onset type is characterized by acute or chronic progressive neurological symptoms and behavioral disturbances. To date, there have been no documented cases worldwide of individuals diagnosed with both HCSD and cobalamin C deficiency.

Case presentation

This report details the case of an 11-year-and-9-month-old female patient from China who presented with symptoms including vomiting, altered consciousness, and a rash. Laboratory evaluations indicated the presence of metabolic acidosis, methylmalonic aciduria, and homocystinuria. Genetic analysis revealed mutations in the MMACHC gene: c.482G > A (p.R161Q) and c.567dup (p.I190Yfs∗13). Additionally, two previously unreported mutations in the HLCS gene, c.1922G > T (p.G641V) and c.1754C > T (p.P585L), were identified. She was diagnosed with Holocarboxylase Synthetase Deficiency and Cobalamin C deficiency. The child showed significant improvement following treatment with hydroxocobalamin, betaine, and biotin.

Conclusion

This article reports a case of adolescent onset HCSD and cobalamin C deficiency. Treatment with hydroxocobalamin, betaine, and biotin is effective. Two novel mutations in the HLCS gene causative for HCSD have been reported, providing a broader foundation for mutational screening and offering insights into the diagnosis and treatment of similar disorders.
背景:全新羧化酶合成酶缺乏症(HCSD)是一种罕见的常染色体隐性遗传疾病,其症状表现为代谢性酸中毒、嗜睡、低血压、癫痫发作和持续性皮疹,通常出现在婴儿期。HLCS基因已被确定为与此病相关的致病性突变的来源。钴胺素C (cblC)缺乏是另一种罕见的常染色体隐性遗传病,由钴胺素代谢缺陷引起,可归因于MMACHC基因突变。这种疾病常导致甲基丙二酸尿和同型半胱氨酸尿,分为早发型和晚发型。迟发型的特点是急性或慢性进行性神经症状和行为障碍。迄今为止,世界范围内还没有同时诊断为HCSD和钴胺素C缺乏症的病例。本报告详细介绍了一名11岁零9个月大的中国女性患者,其症状包括呕吐、意识改变和皮疹。实验室评估显示存在代谢性酸中毒、甲基丙二酸尿和同型半胱氨酸尿。遗传分析显示MMACHC基因突变:c.482G和gt;A (p.R161Q)和c.567dup (p.r 190yfs * 13)。此外,两种先前未报道的HLCS基因突变,c.1922G >;T (p.G641V)和c.1754C >;T (p.P585L),鉴定。她被诊断为全羧化酶合成酶缺乏和钴胺素C缺乏。儿童在接受羟钴胺素、甜菜碱和生物素治疗后表现出明显的改善。结论报告1例青少年发病HCSD合并钴胺素C缺乏症。用羟钴胺素、甜菜碱和生物素治疗是有效的。据报道,导致HCSD的HLCS基因中有两个新的突变,为突变筛查提供了更广泛的基础,并为类似疾病的诊断和治疗提供了见解。
{"title":"Clinical diagnosis, treatment, and genetic analysis of adolescent onset holocarboxylase synthetase deficiency and cobalamin C deficiency: A case report and literature review","authors":"Ye Ren ,&nbsp;Hongxing Dang ,&nbsp;Yueqiang Fu ,&nbsp;Chengjun Liu ,&nbsp;Jing Li ,&nbsp;Jinhua Cai","doi":"10.1016/j.metop.2025.100361","DOIUrl":"10.1016/j.metop.2025.100361","url":null,"abstract":"<div><h3>Background</h3><div>Holocarboxylase Synthetase Deficiency (HCSD) is an uncommon autosomal recessive genetic disorder that manifests with symptoms such as metabolic acidosis, lethargy, hypotonia, seizures, and persistent rashes, typically emerging during infancy. The HLCS gene has been identified as the source of pathogenic mutations associated with this condition. Cobalamin C (cblC) deficiency is another rare autosomal recessive disorder resulting from defects in cobalamin metabolism, attributable to mutations in the MMACHC gene. This disorder often leads to methylmalonic aciduria and homocystinuria and is classified into early-onset and late-onset types. The late-onset type is characterized by acute or chronic progressive neurological symptoms and behavioral disturbances. To date, there have been no documented cases worldwide of individuals diagnosed with both HCSD and cobalamin C deficiency.</div></div><div><h3>Case presentation</h3><div>This report details the case of an 11-year-and-9-month-old female patient from China who presented with symptoms including vomiting, altered consciousness, and a rash. Laboratory evaluations indicated the presence of metabolic acidosis, methylmalonic aciduria, and homocystinuria. Genetic analysis revealed mutations in the MMACHC gene: c.482G &gt; A (p.R161Q) and c.567dup (p.I190Yfs∗13). Additionally, two previously unreported mutations in the HLCS gene, c.1922G &gt; T (p.G641V) and c.1754C &gt; T (p.P585L), were identified. She was diagnosed with Holocarboxylase Synthetase Deficiency and Cobalamin C deficiency. The child showed significant improvement following treatment with hydroxocobalamin, betaine, and biotin.</div></div><div><h3>Conclusion</h3><div>This article reports a case of adolescent onset HCSD and cobalamin C deficiency. Treatment with hydroxocobalamin, betaine, and biotin is effective. Two novel mutations in the HLCS gene causative for HCSD have been reported, providing a broader foundation for mutational screening and offering insights into the diagnosis and treatment of similar disorders.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100361"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remote glucose monitoring and HbA1c improvement among persons with newly diagnosed diabetes mellitus type 2: A multi-center community-based study 新诊断的2型糖尿病患者远程血糖监测和HbA1c改善:一项多中心社区研究
Pub Date : 2025-06-01 Epub Date: 2025-03-05 DOI: 10.1016/j.metop.2025.100355
Mehreen Khan , Lusine Gigoyan , Mary Reed

Aims

Remote monitoring can support patients with Type II diabetes. Still, evidence for improved glucose outcomes in broad community practice patients is extremely limited. We examined remote glucose monitoring in newly diagnosed patients with diabetes to identify its impact on diabetes outcomes.

Methods

In a retrospective cohort study of all adults (age 18–75) with newly diagnosed Type II diabetes February 2020–December 2021 in a large integrated health system, we compared HbA1c (units: percentage, %) outcomes in remote monitoring users to non-users in their first year with diabetes, using propensity-weighted analyses.

Results

Among 35,958 patients, patients age 45+ (vs. age 18–34), who were Asian/Pacific Islander or Hispanic (compared to White), living in more deprived neighborhoods, not using the patient portal, or with baseline HbA1c ≤ 8 were significantly (p < 0.001) less likely to use remote glucose monitoring. After adjustment, remote monitoring use was associated with a 23 % (95 % CI: 17–29 %) higher rate of reaching the HbA1c ≤ 8 % (vs. non-users). In patients starting with HbA1c > 8, remote glucose monitoring use was associated with 0.93 % greater absolute improvement in HbA1c value (vs. non-users, p < 0.05).

Conclusions

Remote glucose monitoring was associated with improved HbA1c among newly diagnosed patients with Type II diabetes.
目的远程监测可以为II型糖尿病患者提供支持。然而,在广泛的社区实践患者中改善血糖结果的证据非常有限。我们检查了新诊断的糖尿病患者的远程血糖监测,以确定其对糖尿病结局的影响。方法在一项回顾性队列研究中,研究人员对2020年2月至2021年12月在一个大型综合卫生系统中新诊断为II型糖尿病的所有成年人(18-75岁)进行了研究,使用倾向加权分析,比较了远程监测用户与非用户在糖尿病第一年的HbA1c(单位:百分比,%)结果。结果在35,958例患者中,年龄45岁以上(vs.年龄18-34岁)、亚裔/太平洋岛民或西班牙裔(与白人相比)、生活在更贫困的社区、未使用患者门户网站或基线HbA1c≤8的患者显著(p <;0.001)不太可能使用远程血糖监测。调整后,远程监测的使用与达到HbA1c≤8%的高23% (95% CI: 17 - 29%)相关(与非用户相比)。从HbA1c开始的患者;8、使用远程血糖监测与HbA1c值的绝对改善相关(与未使用者相比,p <;0.05)。结论远程血糖监测与新诊断II型糖尿病患者HbA1c改善相关。
{"title":"Remote glucose monitoring and HbA1c improvement among persons with newly diagnosed diabetes mellitus type 2: A multi-center community-based study","authors":"Mehreen Khan ,&nbsp;Lusine Gigoyan ,&nbsp;Mary Reed","doi":"10.1016/j.metop.2025.100355","DOIUrl":"10.1016/j.metop.2025.100355","url":null,"abstract":"<div><h3>Aims</h3><div>Remote monitoring can support patients with Type II diabetes. Still, evidence for improved glucose outcomes in broad community practice patients is extremely limited. We examined remote glucose monitoring in newly diagnosed patients with diabetes to identify its impact on diabetes outcomes.</div></div><div><h3>Methods</h3><div>In a retrospective cohort study of all adults (age 18–75) with newly diagnosed Type II diabetes February 2020–December 2021 in a large integrated health system, we compared HbA1c (units: percentage, %) outcomes in remote monitoring users to non-users in their first year with diabetes, using propensity-weighted analyses.</div></div><div><h3>Results</h3><div>Among 35,958 patients, patients age 45+ (vs. age 18–34), who were Asian/Pacific Islander or Hispanic (compared to White), living in more deprived neighborhoods, not using the patient portal, or with baseline HbA1c ≤ 8 were significantly (p &lt; 0.001) less likely to use remote glucose monitoring. After adjustment, remote monitoring use was associated with a 23 % (95 % CI: 17–29 %) higher rate of reaching the HbA1c ≤ 8 % (vs. non-users). In patients starting with HbA1c &gt; 8, remote glucose monitoring use was associated with 0.93 % greater absolute improvement in HbA1c value (vs. non-users, p &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>Remote glucose monitoring was associated with improved HbA1c among newly diagnosed patients with Type II diabetes.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100355"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sleep quality and well-being in obesity-hypoventilation syndrome versus obstructive sleep apnea with obesity: A comparative study 肥胖-低通气综合征与阻塞性睡眠呼吸暂停合并肥胖患者的睡眠质量和幸福感:一项比较研究
Pub Date : 2025-06-01 Epub Date: 2025-05-04 DOI: 10.1016/j.metop.2025.100367
Vasiliki Epameinondas Georgakopoulou , Athina Lazaridou , Athanasios Voulgaris , Kostas Archontogeorgis , Maria Dalamaga , Evangelia Nena , Paschalis Steiropoulos

Background

Only a few studies in the published literature have assessed the well-being, and the sleep quality (SQ) in patients with obesity hypoventilation syndrome (OHS). The aim of this study was to evaluate well-being and SQ in patients with OHS and to compare these outcomes with those of patients with obstructive sleep apnea (OSA) and obesity.

Methods

Consecutive subjects being referred for evaluation of sleep disordered breathing were enrolled in the study. Patients were divided into two groups: Group A: OSA patients with BMI ≥30 kg/m2 and 2) Group B: OHS patients. Well-being was assessed using the World Health Organization-Five Well-Being Index (WHO-5), while sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).

Results

In total 1010 participants (OHS, n = 203) were included in the study. No difference was observed between groups in mean scores of Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), WHO-5, and PSQI questionnaires. In patients with OHS, WHO-5 score was negatively correlated with neck circumference (r = −0.703, p = 0.016) and waist circumference (r = −0.728, p = 0.011). Moreover, PSQI scores in this group were significantly correlated with BMI (r = 0.410, p = 0.038). A lower WHO-5 score was observed in OHS patients with diabetes mellitus compared to non-diabetic patients with OHS (p = 0.049).

Conclusions

Patients with OSA and OHS reported similarly poor well-being and SQ. In patients with OHS, both high neck - and waist circumference were associated with poor well-being, while higher BMI was associated with worse sleep quality. Additionally, the well-being of OHS patients with concomitant diabetes mellitus was worse compared to OHS patients without diabetes mellitus.
在已发表的文献中,只有少数研究评估了肥胖低通气综合征(OHS)患者的幸福感和睡眠质量(SQ)。本研究的目的是评估OHS患者的幸福感和SQ,并将这些结果与阻塞性睡眠呼吸暂停(OSA)和肥胖患者的结果进行比较。方法纳入连续受试者进行睡眠呼吸障碍评估。患者分为两组:A组:BMI≥30 kg/m2的OSA患者;B组:OHS患者。使用世界卫生组织五幸福指数(WHO-5)评估幸福感,使用匹兹堡睡眠质量指数(PSQI)评估睡眠质量。结果共纳入1010名参与者(OHS, n = 203)。Epworth嗜睡量表(ESS)、疲劳严重程度量表(FSS)、WHO-5、PSQI问卷平均得分组间无差异。OHS患者WHO-5评分与颈围(r = - 0.703, p = 0.016)、腰围(r = - 0.728, p = 0.011)呈负相关。此外,该组PSQI评分与BMI呈显著相关(r = 0.410, p = 0.038)。OHS合并糖尿病患者的WHO-5评分低于非糖尿病OHS患者(p = 0.049)。结论OSA和OHS患者报告的幸福感和SQ相似。在OHS患者中,高颈和高腰围与较差的幸福感有关,而高BMI与较差的睡眠质量有关。此外,OHS合并糖尿病患者的幸福感较未合并糖尿病的OHS患者差。
{"title":"Sleep quality and well-being in obesity-hypoventilation syndrome versus obstructive sleep apnea with obesity: A comparative study","authors":"Vasiliki Epameinondas Georgakopoulou ,&nbsp;Athina Lazaridou ,&nbsp;Athanasios Voulgaris ,&nbsp;Kostas Archontogeorgis ,&nbsp;Maria Dalamaga ,&nbsp;Evangelia Nena ,&nbsp;Paschalis Steiropoulos","doi":"10.1016/j.metop.2025.100367","DOIUrl":"10.1016/j.metop.2025.100367","url":null,"abstract":"<div><h3>Background</h3><div>Only a few studies in the published literature have assessed the well-being, and the sleep quality (SQ) in patients with obesity hypoventilation syndrome (OHS). The aim of this study was to evaluate well-being and SQ in patients with OHS and to compare these outcomes with those of patients with obstructive sleep apnea (OSA) and obesity.</div></div><div><h3>Methods</h3><div>Consecutive subjects being referred for evaluation of sleep disordered breathing were enrolled in the study. Patients were divided into two groups: Group A: OSA patients with BMI ≥30 kg/m<sup>2</sup> and 2) Group B: OHS patients. Well-being was assessed using the World Health Organization-Five Well-Being Index (WHO-5), while sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI).</div></div><div><h3>Results</h3><div>In total 1010 participants (OHS, n = 203) were included in the study. No difference was observed between groups in mean scores of Epworth Sleepiness Scale (ESS), Fatigue Severity Scale (FSS), WHO-5, and PSQI questionnaires. In patients with OHS, WHO-5 score was negatively correlated with neck circumference (r = −0.703, p = 0.016) and waist circumference (r = −0.728, p = 0.011). Moreover, PSQI scores in this group were significantly correlated with BMI (r = 0.410, p = 0.038). A lower WHO-5 score was observed in OHS patients with diabetes mellitus compared to non-diabetic patients with OHS (p = 0.049).</div></div><div><h3>Conclusions</h3><div>Patients with OSA and OHS reported similarly poor well-being and SQ. In patients with OHS, both high neck - and waist circumference were associated with poor well-being, while higher BMI was associated with worse sleep quality. Additionally, the well-being of OHS patients with concomitant diabetes mellitus was worse compared to OHS patients without diabetes mellitus.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100367"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recovery time of diabetic ketoacidosis in Africa: Systematic review and meta-analysis 非洲糖尿病酮症酸中毒的恢复时间:系统回顾和荟萃分析
Pub Date : 2025-06-01 Epub Date: 2025-05-15 DOI: 10.1016/j.metop.2025.100370
Tadios Lidetu , Simon Birhanu , Addisu Simachew Asgai , Tsegaamlak Kumelachew Derse , Yideg Abinew , Moges Tadesse , Desalegn Mitiku , Jemberu Chane , Banchamilak Adane , Tadele Kassahun Wudu , Betelhem Mekonnen , Desiyalew Habtamu Tamiru

Background

Diabetes mellitus is a long-term metabolic disease marked by consistently elevated blood glucose levels. Diabetic ketoacidosis is the medical consequence of diabetes mellitus that has the highest attributed fatality rate. Socioeconomically differences affect how long it takes to recover from diabetic ketoacidosis. A few research were carried out in Africa to demonstrate how long diabetic ketoacidosis takes to recover. However, the pooled median recovery time and predictors of diabetic ketoacidosis have not been studied in Africa. Thus, determine the pooled median recovery time and predictors of diabetic ketoacidosis in Africa was the aim of this systematic review and meta-analysis.

Methods

To find available publications, a number of databases were analyzed, including PubMed, Science Direct, Cochrane, Hinari, Google Scholar, grey literature, and articles from various university repository sites. Microsoft Excel version 13 was used to extract and sort the data before exporting it to STATA/MP 17.0 for analysis. The quality of each study was evaluated using the Newcastle-Ottawa Scale. A 95 percent confidence interval Der Simonian random-effects model was employed to investigate the pooled recovery time of diabetic ketoacidosis. Publication bias and heterogeneity were assessed using the Egger's test and I2. Both meta-regression and subgroup analysis were used to determine the potential source of heterogeneity. Statistical significance was defined as P-values below 0.05.

Result

The pooled median recovery time for diabetic ketoacidosis in Africa was 38 h (95 percent CI: 33–43 h), according to this comprehensive review and meta-analysis. Significant heterogeneity is evident when looking at the Galbraith plot with I2 = 100 % (p < 0.001). Research conducted after 2020 revealed that diabetic ketoacidosis has a long recovery time of 40 h (95 percent CI: 3–77 h). However, research with fewer than 300 participants showed that diabetic ketoacidosis recovered more quickly: 18 h (95 percent confidence interval: 12–24 h).

Conclusion

Among patients with diabetic ketoacidosis in Africa, the pooled median recovery time was lengthy. The recovery time from diabetic ketoacidosis was influenced by a number of factors, including the severity of the diabetic ketoacidosis, the delay in starting therapy, and the length of time the patient had diabetes mellitus, and elevated blood glucose levels. Diabetic ketoacidosis recovery time can be shortened by altering these factors.
背景:糖尿病是一种长期的代谢性疾病,其特征是血糖水平持续升高。糖尿病酮症酸中毒是糖尿病的医学后果,死亡率最高。社会经济差异影响糖尿病酮症酸中毒恢复所需的时间。在非洲进行了一些研究,以证明糖尿病酮症酸中毒需要多长时间才能恢复。然而,糖尿病酮症酸中毒的中位恢复时间和预测因素尚未在非洲进行研究。因此,确定非洲糖尿病酮症酸中毒的中位恢复时间和预测因素是本系统综述和荟萃分析的目的。方法通过PubMed、Science Direct、Cochrane、Hinari、谷歌Scholar、灰色文献和各大学知识库网站的文章等数据库进行分析。在导出到STATA/MP 17.0进行分析之前,使用Microsoft Excel version 13对数据进行提取和排序。每个研究的质量用纽卡斯尔-渥太华量表进行评估。采用95%置信区间的Der Simonian随机效应模型研究糖尿病酮症酸中毒的综合恢复时间。采用Egger’s检验和I2评估发表偏倚和异质性。采用meta回归和亚组分析来确定异质性的潜在来源。统计学显著性定义为p值小于0.05。结果根据这项综合综述和荟萃分析,非洲糖尿病酮症酸中毒的中位恢复时间为38小时(95% CI: 33-43小时)。当观察Galbraith图时,I2 = 100% (p <;0.001)。2020年后的研究发现,糖尿病酮症酸中毒的恢复时间长达40小时(95% CI: 3-77小时)。然而,少于300名参与者的研究表明,糖尿病酮症酸中毒恢复得更快:18小时(95%置信区间:12-24小时)。结论非洲地区糖尿病酮症酸中毒患者中位恢复时间较长。糖尿病酮症酸中毒的恢复时间受到许多因素的影响,包括糖尿病酮症酸中毒的严重程度、开始治疗的延迟、患者患有糖尿病的时间长短以及血糖水平升高。改变这些因素可缩短糖尿病酮症酸中毒的恢复时间。
{"title":"Recovery time of diabetic ketoacidosis in Africa: Systematic review and meta-analysis","authors":"Tadios Lidetu ,&nbsp;Simon Birhanu ,&nbsp;Addisu Simachew Asgai ,&nbsp;Tsegaamlak Kumelachew Derse ,&nbsp;Yideg Abinew ,&nbsp;Moges Tadesse ,&nbsp;Desalegn Mitiku ,&nbsp;Jemberu Chane ,&nbsp;Banchamilak Adane ,&nbsp;Tadele Kassahun Wudu ,&nbsp;Betelhem Mekonnen ,&nbsp;Desiyalew Habtamu Tamiru","doi":"10.1016/j.metop.2025.100370","DOIUrl":"10.1016/j.metop.2025.100370","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes mellitus is a long-term metabolic disease marked by consistently elevated blood glucose levels. Diabetic ketoacidosis is the medical consequence of diabetes mellitus that has the highest attributed fatality rate. Socioeconomically differences affect how long it takes to recover from diabetic ketoacidosis. A few research were carried out in Africa to demonstrate how long diabetic ketoacidosis takes to recover. However, the pooled median recovery time and predictors of diabetic ketoacidosis have not been studied in Africa. Thus, determine the pooled median recovery time and predictors of diabetic ketoacidosis in Africa was the aim of this systematic review and meta-analysis.</div></div><div><h3>Methods</h3><div>To find available publications, a number of databases were analyzed, including PubMed, Science Direct, Cochrane, Hinari, Google Scholar, grey literature, and articles from various university repository sites. Microsoft Excel version 13 was used to extract and sort the data before exporting it to STATA/MP 17.0 for analysis. The quality of each study was evaluated using the Newcastle-Ottawa Scale. A 95 percent confidence interval Der Simonian random-effects model was employed to investigate the pooled recovery time of diabetic ketoacidosis. Publication bias and heterogeneity were assessed using the Egger's test and I<sup>2</sup>. Both meta-regression and subgroup analysis were used to determine the potential source of heterogeneity. Statistical significance was defined as P-values below 0.05.</div></div><div><h3>Result</h3><div>The pooled median recovery time for diabetic ketoacidosis in Africa was 38 h (95 percent CI: 33–43 h), according to this comprehensive review and meta-analysis. Significant heterogeneity is evident when looking at the Galbraith plot with I2 = 100 % (p &lt; 0.001). Research conducted after 2020 revealed that diabetic ketoacidosis has a long recovery time of 40 h (95 percent CI: 3–77 h). However, research with fewer than 300 participants showed that diabetic ketoacidosis recovered more quickly: 18 h (95 percent confidence interval: 12–24 h).</div></div><div><h3>Conclusion</h3><div>Among patients with diabetic ketoacidosis in Africa, the pooled median recovery time was lengthy. The recovery time from diabetic ketoacidosis was influenced by a number of factors, including the severity of the diabetic ketoacidosis, the delay in starting therapy, and the length of time the patient had diabetes mellitus, and elevated blood glucose levels. Diabetic ketoacidosis recovery time can be shortened by altering these factors.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100370"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypoglycemia compensation mechanisms in dry fasting 干断食中的低血糖补偿机制
Pub Date : 2025-06-01 Epub Date: 2025-04-15 DOI: 10.1016/j.metop.2025.100363
Ioannis-Eleemon Papagiannopoulos-Vatopaidinos , Maria I. Papagiannopoulou , Eleni N. Dotsika

Background

Dry fasting (DF) presents three primary risks: hypovolemia, hypertonicity, and hypoglycemia. The first two have been shown to be effectively compensated, and the respective mechanisms have been studied. The behavior of glucose has only been roughly described, while the hypoglycemia compensation mechanisms remain unexplored.

Objectives

Studying the glucose behavior, the hypoglycemia compensation mechanisms, and the insulin resistance during DF.

Methods

Following parameters were daily monitored in ten participants undergoing a 5-day DF: Weight, body circumferences, glucose, creatinine clearance (GFR), insulin, HOMA-IR, acetoacetate in 24-h urine, glucagon, growth hormone (GH), IGF-1, TSH, T4, T3, leptin, cholesterol, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides, and the enzymes LDH, CPK, SGPT, SGOT, and γGT.

Results

Weight, body circumferences, TSH, T3, and T4 decreased to minima on Day 5; insulin and HOMA-IR decreased, reaching minima on Day 4; GH, cholesterol, LDL-C, and acetoacetate increased to maxima on Day 5; Glucagon, IGF-1, and GFR increased, presenting maxima on Day 4; Glucose, leptin, and triglycerides exhibited biphasic profiles with minima on Days 3, 3, and 2, respectively; HDL-C, LDH, CPK, SGPT, SGOT, and γGT showed minimal or non-significant changes.

Conclusion

A comprehensive description of glucose behavior and the hypoglycemia compensation mechanisms in DF were presented. DF decreased insulin resistance, likely by improving the blood – cell interphase, and enhanced GFR. The increase in LDL-C, tissue-protecting IGF-1, and late increase in leptin and triglycerides were unexpected. The results may inform the development of novel therapeutic approaches for obesity, metabolic syndrome, type-2-diabetes, non-alcoholic fatty liver disease, adiposity, and atheromatous diseases.
干禁食(DF)有三个主要风险:低血容量、高渗和低血糖。前两者已被证明是有效补偿的,并对各自的机制进行了研究。葡萄糖的行为仅被粗略描述,而低血糖补偿机制仍未探索。目的研究糖尿病患者的血糖行为、低血糖代偿机制及胰岛素抵抗。方法对10名参与者进行为期5天的DF,每天监测以下参数:体重、体围、血糖、肌酐清除率(GFR)、胰岛素、HOMA-IR、24小时尿乙酰乙酸、胰高血糖素、生长激素(GH)、IGF-1、TSH、T4、T3、瘦素、胆固醇、ldl -胆固醇(LDL-C)、hdl -胆固醇(HDL-C)、甘油三酯、LDH、CPK、SGPT、SGOT和γGT。结果体重、体围、TSH、T3、T4在第5天降至最低;胰岛素和HOMA-IR下降,在第4天达到最低;生长激素、胆固醇、LDL-C和乙酰乙酸在第5天达到最大值;胰高血糖素、IGF-1和GFR升高,在第4天达到最大值;葡萄糖、瘦素和甘油三酯分别在第3天、第3天和第2天表现出最小的双相特征;HDL-C、LDH、CPK、SGPT、SGOT和γGT的变化最小或不显著。结论对糖尿病患者的葡萄糖行为和低血糖代偿机制有较全面的描述。DF降低胰岛素抵抗,可能是通过改善血细胞间期和提高GFR。LDL-C、保护组织的IGF-1的升高以及瘦素和甘油三酯的晚期升高都是出乎意料的。该结果可能为肥胖症、代谢综合征、2型糖尿病、非酒精性脂肪性肝病、肥胖和动脉粥样硬化疾病的新治疗方法的发展提供信息。
{"title":"Hypoglycemia compensation mechanisms in dry fasting","authors":"Ioannis-Eleemon Papagiannopoulos-Vatopaidinos ,&nbsp;Maria I. Papagiannopoulou ,&nbsp;Eleni N. Dotsika","doi":"10.1016/j.metop.2025.100363","DOIUrl":"10.1016/j.metop.2025.100363","url":null,"abstract":"<div><h3>Background</h3><div>Dry fasting (DF) presents three primary risks: hypovolemia, hypertonicity, and hypoglycemia. The first two have been shown to be effectively compensated, and the respective mechanisms have been studied. The behavior of glucose has only been roughly described, while the hypoglycemia compensation mechanisms remain unexplored.</div></div><div><h3>Objectives</h3><div>Studying the glucose behavior, the hypoglycemia compensation mechanisms, and the insulin resistance during DF.</div></div><div><h3>Methods</h3><div>Following parameters were daily monitored in ten participants undergoing a 5-day DF: Weight, body circumferences, glucose, creatinine clearance (GFR), insulin, HOMA-IR, acetoacetate in 24-h urine, glucagon, growth hormone (GH), IGF-1, TSH, T<sub>4</sub>, T<sub>3</sub>, leptin, cholesterol, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), triglycerides, and the enzymes LDH, CPK, SGPT, SGOT, and γGT.</div></div><div><h3>Results</h3><div>Weight, body circumferences, TSH, T<sub>3</sub>, and T<sub>4</sub> decreased to minima on Day 5; insulin and HOMA-IR decreased, reaching minima on Day 4; GH, cholesterol, LDL-C, and acetoacetate increased to maxima on Day 5; Glucagon, IGF-1, and GFR increased, presenting maxima on Day 4; Glucose, leptin, and triglycerides exhibited biphasic profiles with minima on Days 3, 3, and 2, respectively; HDL-C, LDH, CPK, SGPT, SGOT, and γGT showed minimal or non-significant changes.</div></div><div><h3>Conclusion</h3><div>A comprehensive description of glucose behavior and the hypoglycemia compensation mechanisms in DF were presented. DF decreased insulin resistance, likely by improving the blood – cell interphase, and enhanced GFR. The increase in LDL-C, tissue-protecting IGF-1, and late increase in leptin and triglycerides were unexpected. The results may inform the development of novel therapeutic approaches for obesity, metabolic syndrome, type-2-diabetes, non-alcoholic fatty liver disease, adiposity, and atheromatous diseases.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100363"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143838276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetic ketoacidosis treatment outcomes and associated factors among adult diabetic patients in Ethiopia: A systematic review and meta-analysis 埃塞俄比亚成年糖尿病患者的糖尿病酮症酸中毒治疗结果和相关因素:系统回顾和荟萃分析
Pub Date : 2025-03-25 DOI: 10.1016/j.metop.2025.100360
Tsegaamlak Kumelachew Derse , Desalegn Metiku Kidie , Addisu Simachew Asgai , Tadios lidetu , Moges Tadesse Abebe

Background

Diabetic ketoacidosis is a severe complication of diabetes that can threaten life and has a considerable effect on healthcare systems, especially in developing nations such as Ethiopia. Although it is clinically significant, comprehensive data on the factors that lead to unsatisfactory treatment outcomes in diabetic ketoacidosis patients in Ethiopia are lacking. This review aims to investigate and evaluate unsatisfactory treatment outcomes and multiple contributing factors related to diabetic ketoacidosis among patients with diabetes in Ethiopia. This review seeks to identify these factors to provide insights that can guide improvements in the management and treatment of diabetic patients.

Methods

Articles documenting unfavorable treatment outcomes and related aspects of diabetic ketoacidosis among Ethiopian diabetes patients were meticulously sought from various databases, including PubMed/MEDLINE, the Cochrane Library, Science Direct, HINARI, Google Scholar, and gray literature. After the data were extracted, they were imported into Stata software version 17 for analysis. The Cochrane Q test and I2 statistic were used to evaluate heterogeneity.

Results

A total of 580 duplicates were eliminated from the initial set of 1578 papers obtained from PubMed (3), Google Scholar (1,550), HINARI (11), Science Direct (13), and the Cochrane Library (1). The pooled prevalence of poor treatment outcomes for diabetic ketoacidosis was 8 %. Key risk factors for poor treatment outcomes included a Glasgow Coma Scale (GCS) score of less than 15 (POR = 3.16; 95 % CI: 1.52–4.80), sepsis (POR = 2.92; 95 % CI: 1.12–4.72), and comorbidities (POR = 3.66; 95 % CI: 1.64–5.68).

Conclusion

The pooled prevalence of poor treatment outcomes of diabetic ketoacidosis in Ethiopia was high. A GCS score of less than 15, sepsis, and comorbidities were identified as significant risk factors for poor treatment outcomes in diabetic ketoacidosis patients. Addressing and minimizing these factors could help reduce the incidence of poor treatment outcomes in diabetic ketoacidosis patients in Ethiopia.
糖尿病酮症酸中毒是糖尿病的一种严重并发症,可威胁生命,对医疗保健系统有相当大的影响,特别是在埃塞俄比亚等发展中国家。虽然具有临床意义,但埃塞俄比亚缺乏导致糖尿病酮症酸中毒患者治疗结果不满意的因素的综合数据。本综述旨在调查和评价埃塞俄比亚糖尿病患者不满意的治疗结果和与糖尿病酮症酸中毒相关的多种因素。本综述旨在确定这些因素,为指导糖尿病患者管理和治疗的改进提供见解。方法从PubMed/MEDLINE、Cochrane图书馆、Science Direct、HINARI、谷歌Scholar和灰色文献等数据库中仔细检索记录埃塞俄比亚糖尿病患者不良治疗结果和糖尿病酮症酸中毒相关方面的文章。数据提取后,导入Stata软件版本17进行分析。采用Cochrane Q检验和I2统计量评价异质性。结果从PubMed(3)、谷歌Scholar(1550)、HINARI(11)、Science Direct(13)和Cochrane图书馆(1)获得的1578篇论文中,共剔除了580个重复。糖尿病酮症酸中毒治疗不良的总发生率为8%。不良治疗结果的关键危险因素包括格拉斯哥昏迷评分(GCS)低于15分(POR = 3.16;95% CI: 1.52-4.80),脓毒症(POR = 2.92;95% CI: 1.12-4.72),合并症(POR = 3.66;95% ci: 1.64-5.68)。结论埃塞俄比亚糖尿病酮症酸中毒治疗不良的总发生率较高。GCS评分小于15、脓毒症和合并症被认为是糖尿病酮症酸中毒患者治疗结果不佳的重要危险因素。解决和尽量减少这些因素可能有助于减少埃塞俄比亚糖尿病酮症酸中毒患者治疗结果不佳的发生率。
{"title":"Diabetic ketoacidosis treatment outcomes and associated factors among adult diabetic patients in Ethiopia: A systematic review and meta-analysis","authors":"Tsegaamlak Kumelachew Derse ,&nbsp;Desalegn Metiku Kidie ,&nbsp;Addisu Simachew Asgai ,&nbsp;Tadios lidetu ,&nbsp;Moges Tadesse Abebe","doi":"10.1016/j.metop.2025.100360","DOIUrl":"10.1016/j.metop.2025.100360","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic ketoacidosis is a severe complication of diabetes that can threaten life and has a considerable effect on healthcare systems, especially in developing nations such as Ethiopia. Although it is clinically significant, comprehensive data on the factors that lead to unsatisfactory treatment outcomes in diabetic ketoacidosis patients in Ethiopia are lacking. This review aims to investigate and evaluate unsatisfactory treatment outcomes and multiple contributing factors related to diabetic ketoacidosis among patients with diabetes in Ethiopia. This review seeks to identify these factors to provide insights that can guide improvements in the management and treatment of diabetic patients.</div></div><div><h3>Methods</h3><div>Articles documenting unfavorable treatment outcomes and related aspects of diabetic ketoacidosis among Ethiopian diabetes patients were meticulously sought from various databases, including PubMed/MEDLINE, the Cochrane Library, Science Direct, HINARI, Google Scholar, and gray literature. After the data were extracted, they were imported into Stata software version 17 for analysis. The Cochrane Q test and I<sup>2</sup> statistic were used to evaluate heterogeneity.</div></div><div><h3>Results</h3><div>A total of 580 duplicates were eliminated from the initial set of 1578 papers obtained from PubMed (3), Google Scholar (1,550), HINARI (11), Science Direct (13), and the Cochrane Library (1). The pooled prevalence of poor treatment outcomes for diabetic ketoacidosis was 8 %. Key risk factors for poor treatment outcomes included a Glasgow Coma Scale (GCS) score of less than 15 (POR = 3.16; 95 % CI: 1.52–4.80), sepsis (POR = 2.92; 95 % CI: 1.12–4.72), and comorbidities (POR = 3.66; 95 % CI: 1.64–5.68).</div></div><div><h3>Conclusion</h3><div>The pooled prevalence of poor treatment outcomes of diabetic ketoacidosis in Ethiopia was high. A GCS score of less than 15, sepsis, and comorbidities were identified as significant risk factors for poor treatment outcomes in diabetic ketoacidosis patients. Addressing and minimizing these factors could help reduce the incidence of poor treatment outcomes in diabetic ketoacidosis patients in Ethiopia.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"26 ","pages":"Article 100360"},"PeriodicalIF":0.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gender based difference in glycemic control and diabetes related chronic complications among type 2 diabetic patients in Debre Berhan city public hospitals 德伯尔汉市公立医院2型糖尿病患者血糖控制及糖尿病相关慢性并发症的性别差异
Pub Date : 2025-03-01 Epub Date: 2025-01-23 DOI: 10.1016/j.metop.2025.100349
Enguday Demeke Gebeyaw , Girma Deshimo Lema

Introduction

Type 2 diabetes mellitus (T2DM) is a growing public health concern, particularly in low- and middle-income countries like Ethiopia. There is limited data on gender differences in glycemic control and diabetes related chronic complications in Ethiopia. This study aimed to assess gender-based difference in glycemic control and diabetes related chronic complications among T2DM patients in Debre Berhan public hospitals, Ethiopia.

Methods

A comparative cross-sectional study was carried out at public hospitals in Debre Berhan. Data were gathered from 258 T2DM patients (129 men and 129 women). Using Hemoglobin A1c (HgA1c), level of glycemic control was assessed. To compare gender differences in diabetes related chronic complications and glycemic control, the chi-square test and Independent sample t-test were employed. However logistic regression was employed to identify gender-specific factors of poor glycemic control.

Results

Women had poorer glycemic control, with a mean difference of 0.51 (95 % CI: 0.04–0.97) as compared with men. Alcohol consumption (AOR = 3.2; 95 % CI: 1.25–7.98), drug non-adherence (AOR = 4.1; 95 % CI: 1.01–17.54) and diabetic complications (AOR = 0.3; 95 % CI: 0.10–0.88) were significant factors for poor glycemic control in men. For women, rural residence (AOR = 0.2; 95 % CI: 0.03–0.58), duration of diabetes >5 years (AOR = 4.3; 95 % CI: 1.15–16.17), and drug non-adherence (AOR = 4.7; 95 % CI: 1.14–19.42) were significant factors for poor glycemic control. There were no significant gender differences in diabetes related chronic complications.

Conclusion

This study revealed significant gender differences in glycemic control among T2DM patients. Female patients experienced worse glycemic control. There were no gender differences in the prevalence of diabetes related chronic complications. This study highlights the importance of considering both general and specific factors when assessing and improving glycemic control in T2DM. Future studies should involve large sample sizes and gender focused studies to gain a deeper understanding of the relevant factors.
2型糖尿病(T2DM)是一个日益严重的公共卫生问题,特别是在埃塞俄比亚等低收入和中等收入国家。在埃塞俄比亚,关于血糖控制和糖尿病相关慢性并发症的性别差异的数据有限。本研究旨在评估埃塞俄比亚Debre Berhan公立医院T2DM患者血糖控制和糖尿病相关慢性并发症的性别差异。方法采用比较横断面研究方法,对德伯尔省公立医院进行调查。数据来自258名T2DM患者(129名男性和129名女性)。采用糖化血红蛋白(HgA1c)评估血糖控制水平。比较糖尿病相关慢性并发症和血糖控制的性别差异,采用卡方检验和独立样本t检验。然而,采用逻辑回归来确定血糖控制不良的性别特异性因素。结果与男性相比,女性血糖控制较差,平均差值为0.51 (95% CI: 0.04-0.97)。饮酒(AOR = 3.2;95% CI: 1.25-7.98),药物不依从(AOR = 4.1;95% CI: 1.01-17.54)和糖尿病并发症(AOR = 0.3;95% CI: 0.10-0.88)是男性血糖控制不良的重要因素。对于妇女,农村居住(AOR = 0.2;95% CI: 0.03-0.58),糖尿病病程>;5年(AOR = 4.3;95% CI: 1.15-16.17)和药物不依从(AOR = 4.7;95% CI: 1.14-19.42)是血糖控制不良的重要因素。糖尿病相关慢性并发症的性别差异不显著。结论T2DM患者血糖控制存在显著的性别差异。女性患者血糖控制较差。糖尿病相关慢性并发症的患病率没有性别差异。本研究强调了在评估和改善T2DM患者血糖控制时综合考虑一般因素和特殊因素的重要性。今后的研究应包括大样本量和以性别为重点的研究,以便更深入地了解有关因素。
{"title":"Gender based difference in glycemic control and diabetes related chronic complications among type 2 diabetic patients in Debre Berhan city public hospitals","authors":"Enguday Demeke Gebeyaw ,&nbsp;Girma Deshimo Lema","doi":"10.1016/j.metop.2025.100349","DOIUrl":"10.1016/j.metop.2025.100349","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2DM) is a growing public health concern, particularly in low- and middle-income countries like Ethiopia. There is limited data on gender differences in glycemic control and diabetes related chronic complications in Ethiopia. This study aimed to assess gender-based difference in glycemic control and diabetes related chronic complications among T2DM patients in Debre Berhan public hospitals, Ethiopia.</div></div><div><h3>Methods</h3><div>A comparative cross-sectional study was carried out at public hospitals in Debre Berhan. Data were gathered from 258 T2DM patients (129 men and 129 women). Using Hemoglobin A1c (HgA1c), level of glycemic control was assessed. To compare gender differences in diabetes related chronic complications and glycemic control, the chi-square test and Independent sample <em>t</em>-test were employed. However logistic regression was employed to identify gender-specific factors of poor glycemic control.</div></div><div><h3>Results</h3><div>Women had poorer glycemic control, with a mean difference of 0.51 (95 % CI: 0.04–0.97) as compared with men. Alcohol consumption <em>(</em>AOR = 3.2; 95 % CI: 1.25–7.98), drug non-adherence <em>(</em>AOR = 4.1; 95 % CI: 1.01–17.54) and diabetic complications <em>(</em>AOR = 0.3; 95 % CI: 0.10–0.88) were significant factors for poor glycemic control in men. For women, rural residence <em>(</em>AOR = 0.2; 95 % CI: 0.03–0.58), duration of diabetes &gt;5 years <em>(</em>AOR = 4.3; 95 % CI: 1.15–16.17)<em>,</em> and drug non-adherence <em>(</em>AOR = 4.7; 95 % CI: 1.14–19.42) were significant factors for poor glycemic control. There were no significant gender differences in diabetes related chronic complications.</div></div><div><h3>Conclusion</h3><div>This study revealed significant gender differences in glycemic control among T2DM patients. Female patients experienced worse glycemic control. There were no gender differences in the prevalence of diabetes related chronic complications. This study highlights the importance of considering both general and specific factors when assessing and improving glycemic control in T2DM. Future studies should involve large sample sizes and gender focused studies to gain a deeper understanding of the relevant factors.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"25 ","pages":"Article 100349"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143097819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SPT: A new contributor to trans fatty acid-induced atherosclerosis SPT:反式脂肪酸诱导的动脉粥样硬化的新贡献者
Pub Date : 2025-03-01 Epub Date: 2024-12-25 DOI: 10.1016/j.metop.2024.100340
Chengbin Li, Junli Liu, Bin Liang
{"title":"SPT: A new contributor to trans fatty acid-induced atherosclerosis","authors":"Chengbin Li,&nbsp;Junli Liu,&nbsp;Bin Liang","doi":"10.1016/j.metop.2024.100340","DOIUrl":"10.1016/j.metop.2024.100340","url":null,"abstract":"","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"25 ","pages":"Article 100340"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143611695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autoimmune protocol diet: A personalized elimination diet for patients with autoimmune diseases 自身免疫方案饮食:一种针对自身免疫性疾病患者的个性化消除饮食。
Pub Date : 2025-03-01 Epub Date: 2024-12-30 DOI: 10.1016/j.metop.2024.100342
Eleni C. Pardali , Arriana Gkouvi , Kalliopi K. Gkouskou , Anastasios C. Manolakis , Christina Tsigalou , Dimitrios G. Goulis , Dimitrios P. Bogdanos , Maria G. Grammatikopoulou
The autoimmune protocol diet (AIP) is a personalized elimination diet that aims to determine and exclude the foods that might trigger immune responses, leading to inflammation and symptomatology associated with autoimmune diseases. Focusing on gut health and the importance of the gut microbiome in immune regulation and overall well-being, the AIP starts by eliminating foods that might create negative effects on the patients and continues by developing a personalized and tailored diet plan for them. This comprehensive approach aims to mitigate symptoms and improve quality of life of individuals with autoimmune conditions. This review presents and critically appraises current knowledge on the AIP protocol, highlight any oversights, and discuss findings from relevant clinical trials.
自身免疫方案饮食(AIP)是一种个性化的消除饮食,旨在确定和排除可能引发免疫反应的食物,导致与自身免疫性疾病相关的炎症和症状。AIP专注于肠道健康和肠道微生物群在免疫调节和整体健康中的重要性,从消除可能对患者产生负面影响的食物开始,并继续为他们制定个性化和量身定制的饮食计划。这种综合方法旨在减轻自身免疫性疾病患者的症状并改善其生活质量。这篇综述提出并批判性地评价了目前关于AIP方案的知识,强调了任何疏忽,并讨论了相关临床试验的发现。
{"title":"Autoimmune protocol diet: A personalized elimination diet for patients with autoimmune diseases","authors":"Eleni C. Pardali ,&nbsp;Arriana Gkouvi ,&nbsp;Kalliopi K. Gkouskou ,&nbsp;Anastasios C. Manolakis ,&nbsp;Christina Tsigalou ,&nbsp;Dimitrios G. Goulis ,&nbsp;Dimitrios P. Bogdanos ,&nbsp;Maria G. Grammatikopoulou","doi":"10.1016/j.metop.2024.100342","DOIUrl":"10.1016/j.metop.2024.100342","url":null,"abstract":"<div><div>The autoimmune protocol diet (AIP) is a personalized elimination diet that aims to determine and exclude the foods that might trigger immune responses, leading to inflammation and symptomatology associated with autoimmune diseases. Focusing on gut health and the importance of the gut microbiome in immune regulation and overall well-being, the AIP starts by eliminating foods that might create negative effects on the patients and continues by developing a personalized and tailored diet plan for them. This comprehensive approach aims to mitigate symptoms and improve quality of life of individuals with autoimmune conditions. This review presents and critically appraises current knowledge on the AIP protocol, highlight any oversights, and discuss findings from relevant clinical trials.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"25 ","pages":"Article 100342"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the anti-inflammatory potential of vitamin D in cardiometabolic diseases 探索维生素D在心血管代谢疾病中的抗炎作用。
Pub Date : 2025-03-01 Epub Date: 2025-01-09 DOI: 10.1016/j.metop.2025.100348
Kabelo Mokgalaboni
The prevalence of cardiometabolic diseases is rising, and this is fuelled by inflammation, which tends to be worse in individuals with vitamin D (VD) deficiency. While non-steroidal anti-inflammatory interventions are available, they present with coagulation events. Hence, alternative therapy in the form of VD supplements is gaining research interest. This study reviewed the effect of VD supplementation on inflammation, focusing on nuclear factor kappa-beta (NF-κβ), tumour necrosis factor-alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) across different cardiometabolic disease. Thirty-seven studies, 16 rodent models and 21 clinical studies were evaluated. The study considered evidence from rodent models to understand the effect of VD on these markers of inflammation and its translatability to clinical studies. While the potential benefits of VD were notable in rodents, these effects were less consistent in clinical studies. Notably, rodent models showed a more pronounced impact of VD in reducing NF-κβ and TNF-α; however, clinical trials reported conflicting findings. Furthermore, the VD was important in reducing MCP-1 across different rodent models; this was partially demonstrated in clinical trials. Based on these findings, VD modulates inflammation in cardiometabolic disease by inhibiting the activation of NF-κβ and suppressing the production of TNF-α and MCP-1. Although VD has some possible benefits in rodent models, the translatability of these findings in clinical trials is limited. Hence, the presented evidence in this study calls for further randomised controlled trials to assess the effect of VD on inflammation in patients living with different conditions as a therapy to curb the inflammation and the risk thereof. Future trials should also focus on exploring the VD dose-response, optimal dose, and duration of VD intervention among these patients that may offer optimal benefits on inflammation.
心脏代谢疾病的发病率正在上升,这是由炎症引起的,而炎症在维生素D (VD)缺乏的个体中往往更严重。虽然非甾体抗炎干预措施是可用的,但它们存在凝血事件。因此,以VD补充剂形式的替代疗法正在获得研究兴趣。本研究综述了VD补充对炎症的影响,重点关注不同心脏代谢疾病的核因子κβ (NF-κβ)、肿瘤坏死因子α (TNF-α)和单核细胞趋化蛋白-1 (MCP-1)。对37项研究、16种啮齿动物模型和21项临床研究进行了评价。该研究考虑了来自啮齿动物模型的证据,以了解VD对这些炎症标志物的影响及其对临床研究的可翻译性。虽然VD的潜在益处在啮齿类动物中是显著的,但这些影响在临床研究中不太一致。值得注意的是,在啮齿动物模型中,VD对NF-κβ和TNF-α的降低作用更为明显;然而,临床试验报告了相互矛盾的结果。此外,VD在不同啮齿动物模型中对降低MCP-1有重要作用;这在临床试验中得到了部分证明。基于这些发现,VD通过抑制NF-κβ的激活和抑制TNF-α和MCP-1的产生来调节心脏代谢疾病的炎症。虽然VD在啮齿动物模型中有一些可能的益处,但这些发现在临床试验中的可翻译性是有限的。因此,本研究提出的证据需要进一步的随机对照试验来评估VD对不同条件患者炎症的影响,作为一种抑制炎症及其风险的治疗方法。未来的试验还应该集中在探索这些患者的VD剂量反应、最佳剂量和VD干预的持续时间,这些患者可能对炎症有最佳的益处。
{"title":"Exploring the anti-inflammatory potential of vitamin D in cardiometabolic diseases","authors":"Kabelo Mokgalaboni","doi":"10.1016/j.metop.2025.100348","DOIUrl":"10.1016/j.metop.2025.100348","url":null,"abstract":"<div><div>The prevalence of cardiometabolic diseases is rising, and this is fuelled by inflammation, which tends to be worse in individuals with vitamin D (VD) deficiency. While non-steroidal anti-inflammatory interventions are available, they present with coagulation events. Hence, alternative therapy in the form of VD supplements is gaining research interest. This study reviewed the effect of VD supplementation on inflammation, focusing on nuclear factor kappa-beta (NF-κβ), tumour necrosis factor-alpha (TNF-α) and monocyte chemoattractant protein-1 (MCP-1) across different cardiometabolic disease. Thirty-seven studies, 16 rodent models and 21 clinical studies were evaluated. The study considered evidence from rodent models to understand the effect of VD on these markers of inflammation and its translatability to clinical studies. While the potential benefits of VD were notable in rodents, these effects were less consistent in clinical studies. Notably, rodent models showed a more pronounced impact of VD in reducing NF-κβ and TNF-α; however, clinical trials reported conflicting findings. Furthermore, the VD was important in reducing MCP-1 across different rodent models; this was partially demonstrated in clinical trials. Based on these findings, VD modulates inflammation in cardiometabolic disease by inhibiting the activation of NF-κβ and suppressing the production of TNF-α and MCP-1. Although VD has some possible benefits in rodent models, the translatability of these findings in clinical trials is limited. Hence, the presented evidence in this study calls for further randomised controlled trials to assess the effect of VD on inflammation in patients living with different conditions as a therapy to curb the inflammation and the risk thereof. Future trials should also focus on exploring the VD dose-response, optimal dose, and duration of VD intervention among these patients that may offer optimal benefits on inflammation.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"25 ","pages":"Article 100348"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Metabolism open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1